Potential protective immunogenicity of tetanus toxoid, diphtheria toxoid and Cross Reacting Material 197 (CRM197) when used as carrier proteins in glycoconjugates.
When tetanus toxoid (TT), diphtheria toxoid (DT) or Cross Reacting Material 197 (CRM197), a non-toxic diphtheria toxin mutant protein, are used as carrier proteins in glycoconjugate vaccines, these carriers induce a protein specific antibody response as measured by in vitro assays. Here, it was evaluated whether or not glycoconjugates based on TT, DT or CRM197 can induce a protective immune response as measured by potency tests according to the European Pharmacopoeia. It could be shown, that the conjugate carriers TT and DT can induce a protective immune response against a lethal challenge by toxins in animals, while glycoconjugates based on CRM197 failed to induce a protective immune response. Opportunities for new applications of glycoconjugates are discussed.
a GSK Vaccines GmbH , Marburg , Germany.
Michael
M
Bröker
D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood; D001426:Bacterial Proteins / Q000276:immunology*; D002352:Carrier Proteins / Q000276:immunology*; D004165:Diphtheria / Q000517:prevention & control; D004168:Diphtheria Toxoid / Q000276:immunology*; D004195:Disease Models, Animal; D006001:Glycoconjugates / Q000276:immunology; D016019:Survival Analysis; D013742:Tetanus / Q000517:prevention & control; D013745:Tetanus Toxoid / Q000276:immunology*; D018074:Vaccines, Conjugate / Q000008:administration & dosage / Q000276:immunology
D000907:Antibodies, Bacterial; D001426:Bacterial Proteins; D002352:Carrier Proteins; D004168:Diphtheria Toxoid; D006001:Glycoconjugates; D013745:Tetanus Toxoid; D018074:Vaccines, Conjugate; C028581:CRM197 (non-toxic variant of diphtheria toxin)
Cross Reacting Material 197; carrier proteins; combination vaccines; diphtheria toxoid; glycoconjugates; protective immunity; tetanus toxoid